2012

February 14, 2012
BTG plc: Directorate Change Amendment

London, UK, 14 February 2012 BTG plc (LSE: BGC), the specialist healthcare company, announces that Rolf Soderstrom will no longer be leaving the company at the end of March and will continue in...

January 30, 2012
BTG Announces Positive Data from First US Phase III Trial of Varisolve®

London, UK, 30 January 2012 Study meets all primary, secondary and tertiary endpoints BTG plc (LSE: BGC), the specialist healthcare company, today announces the successful outcome of VANISH-2, the...

January 25, 2012
BTG plc: Interim Management Statement

London, UK, 25 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today publishes its interim management statement for the period from 1 October 2011 to 24 January 2012. Trading...

January 18, 2012
BTG plc: Voraxaze® (glucarpidase) receives US regulatory approval

London, UK, 18 January 2012 BTG plc (LSE: BGC), the specialist healthcare company, today announces that it has received regulatory approval from the US Food and Drug Administration (FDA) for its...

January 11, 2012
BTG to present at the 30th Annual J.P. Morgan Healthcare Conference

London, UK, 11 January 2012 BTG plc (LSE: BGC), the specialist healthcare company today announces that it will be presenting at the 30th Annual J.P. Morgan Conference on Wednesday 11 January at...

Show 5102550100 per page
Top